ÂÜÀòÂÒÂ×

Charles Sentman is a professor in the department of microbiology & immunology at the Geisel School of Medicine at Dartmouth and the director of the Center for Synthetic Immunity. Dr. Sentman’s research interests are natural killer (NK) cell recognition mechanisms, the role of NK cells as a part of the immune defense against cancer and infection, and how NK cell and T-cell effector mechanisms affect the tumor microenvironment. His laboratory is focused on the development of novel immunotherapy strategies for cancer, and there are several major areas of research: chimeric antigen receptor-based immunotherapy, bi-specific engager targeting of tumors, and development of novel signaling platforms for cell-based therapies. Earlier in his career, Dr. Sentman worked as a team leader and section leader at AstraZeneca R&D in Lund, Sweden. Dr. Sentman received a B.S. from the University of Illinois and a Ph.D. from the University of Texas Southwestern Medical Center. He completed postdoctoral training at Washington University and the Karolinska Institute.